Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of 22.7 per cent of their body weight. That was only marginally ahead of results for Mounjaro, an existing rival treatment made by Eli Lilly.
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class ...
Proficio Capital Partners LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in the 4th quarter, ...
Get key updates on stock ratings this week, from Intel's leadership-driven upgrade to Apple's tariff challenges.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback